Doug Coil

Over thirty years of experience in oncology drug development. His background covers a broad range of the drug development process, including budgeting, contract negotiations and business development. He was the Clinical Director at the Stehlin Foundation for Cancer Research where he lead both the pre-clinical drug development program and the clinical program including protocol development, FDA IND submissions, and several FDA Phase I and Phase II studies involving CPT (camptothecin) based drugs. Cao Pharmaceuticals has leveraged this experience to receive FDA approval for the current and ongoing Phase I study of CZ48, the planning of several Phase II studies of CZ48, and to guide from a clinical perspective the development of the pipeline drugs.